Analysis Tools
mortality/aging
 |
• homozygous males have a mean life span of greater than 21 months, 3 to 4 time longer than non-homozygous males
|
endocrine/exocrine glands
|
|
• seen in about 20% of mice
|
immune system
|
|
• seen in about 20% of mice
|
|
|
• decrease in CD4+ T cells with age is less pronounced than in non-homozygous males
|
|
|
• do not develop severe monocytosis, unlike non-homozygous males
|
|
|
• at 3 to 5 months of age relative to non-homozygous males; however by 2 years of age IgG levels are similar to those in 2 to 3 month old early dying males
|
|
|
• minimal signs of autoimmune disease are seen at 8 months of age unlike non-homozygous males
|
|
|
• anti-nuclear antibodies are decreased relative to non-homozygous males
|
cardiovascular system
|
N |
• no arteritic or degenerative vascular disease or myocardial infarctions are detected
|
neoplasm
|
|
• seen in about 20% of mice
|
|
|
• seen in about 20% of mice
|
renal/urinary system
|
N |
• glomerular lesions characteristic of aging are seen at 28 months of age but homozygotes do not develop proliferative glomerulonephritis
|
hematopoietic system
|
|
• seen in about 20% of mice
|
|
|
• decrease in CD4+ T cells with age is less pronounced than in non-homozygous males
|
|
|
• do not develop severe monocytosis, unlike non-homozygous males
|
|
|
• at 3 to 5 months of age relative to non-homozygous males; however by 2 years of age IgG levels are similar to those in 2 to 3 month old early dying males
|
